Stevanato Group SpA (STVN)

Currency in USD
21.52
+0.27(+1.27%)
Closed·
21.52+0.01(+0.05%)
·
STVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20.9521.61
52 wk Range
12.8928.00
Key Statistics
Prev. Close
21.25
Open
21.24
Day's Range
20.95-21.61
52 wk Range
12.89-28
Volume
514.96K
Average Volume (3m)
359.69K
1-Year Change
-3.7567%
Book Value / Share
6.48
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
STVN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.74
Upside
+14.95%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Stevanato Group SpA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

9 Buy
3 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 24.74
(+14.95% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Buy26.00+20.87%-New CoverageJul 30, 2026
TD Cowen
Buy25.00+16.23%-New CoverageJun 16, 2026
Wolfe Research
Buy21.00-2.37%-New CoverageJun 01, 2026
Morgan Stanley
Hold19.00-11.67%24.00MaintainMar 06, 2026
KeyBanc
Buy32.00+48.77%37.00MaintainMar 05, 2026

Stevanato Group SpA Earnings Call Summary for Q2/2026

  • Stevanato Q2 2026 adjusted EPS of $0.14 beat estimates by $0.01; revenue rose 8% to EUR 302M, shares fell 3.21% on cash flow concerns.
  • Adjusted EBITDA jumped 21% to EUR 78.7M with margin expanding 180bps to 26%; high-value solutions grew 16%, now 45% of total revenue.
  • Company divested lower-margin Balda C. Brewer business; negative EUR 32M free cash flow driven by EUR 52M capex for U.S. and European plants.
  • Full-year 2026 guidance maintained at EUR 1.26B-1.28B revenue, EUR 335M-345M EBITDA; expects breakeven to EUR 20M positive free cash flow.
  • Alina drug delivery platform received approval for diabetes and weight management; biologics and GLP-1 therapies represent 22-23% of revenue.
Last Updated: 2026-08-04, 09:54 a/m
Read Full Transcript

Earnings

Latest Release
Aug 04, 2026
EPS / Forecast
0.14 / 0.13
Revenue / Forecast
302M / 298.64M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.49%
Dividend Yield
0.30%
Industry Median 1.47%
Annualized payout
0.06
Paid annually
5-Years Growth
-79.83%
Growth Streak

STVN Income Statement

Compare STVN to Peers and Sector

Metrics to compare
STVN
Peers
Sector
Relationship
P/E Ratio
37.5x1.3x−0.3x
PEG Ratio
-0.060.00
Price/Book
3.3x0.9x2.6x
Price / LTM Sales
4.1x0.6x3.1x
Upside (Analyst Target)
17.1%6.6%48.3%
Fair Value Upside
Unlock5.4%6.7%Unlock

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
24.95M10.26%530.12M
Other Institutional Investors
248.54M89.74%5.28B
Public Companies & Retail Investors
0.000.00%0.00
Total
273.49M100.00%5.81B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Stevanato Holding S.R.L.91.83%223,293,9764,744,997
Conestoga Capital Advisors, LLC2.88%7,007,613148,912

People Also Watch

11.948
BMPS
+0.29%
4.5600
SPMI
+3.64%
12.83
FCT
+2.48%
5.9640
CPRI
+0.24%
4.237
NEXII
+2.37%

FAQ

What Is the Stevanato Group SpA (STVN) Stock Price Today?

The Stevanato Group SpA stock price today is 21.52 USD.

What Stock Exchange Does Stevanato Group SpA Trade On?

Stevanato Group SpA is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Stevanato Group SpA?

The stock symbol for Stevanato Group SpA is "STVN."

Does Stevanato Group SpA Pay Dividends? What’s The Current Dividend Yield?

The Stevanato Group SpA dividend yield is 0.3%.

What Is the Stevanato Group SpA Market Cap?

As of today, Stevanato Group SpA market cap is 5.86B USD.

What Is Stevanato Group SpA's Earnings Per Share (TTM)?

The Stevanato Group SpA EPS (TTM) is 0.49.

When Is the Next Stevanato Group SpA Earnings Date?

Stevanato Group SpA will release its next earnings report on Nov 10, 2026.

From a Technical Analysis Perspective, Is STVN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Stevanato Group SpA Stock Split?

Stevanato Group SpA has split 0 times.

How Many Employees Does Stevanato Group SpA Have?

Stevanato Group SpA has 6010 employees.

What is the current trading status of Stevanato Group SpA (STVN)?

As of Aug 13, 2026, Stevanato Group SpA (STVN) is trading at a price of 21.52 USD, with a previous close of 21.25 USD. The stock has fluctuated within a day range of 20.95 USD to 21.61 USD, while its 52-week range spans from 12.89 USD to 28.00 USD.

What Is Stevanato Group SpA (STVN) Price Target According to Analysts?

The average 12-month price target for Stevanato Group SpA is 24.74 USD, with a high estimate of 32 USD and a low estimate of 20 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +14.95% Upside potential.

What Is the STVN After Hours Price?

STVN's last after hours stock price is 21.52 USD, the stock has decreased by 0.01, or 0.05%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.